DR. CARL T MINATOYA MD
Prescription History 1518974021
Ophthalmology in Honolulu, HI

NPI Status: Active since August 01, 2006

Contact Information

1003 PENSACOLA ST
HONOLULU, HI
ZIP 96814
Phone: (808) 597-1133
Fax: (808) 596-0251

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. CARL T MINATOYA MD, an active Ophthalmology specialist practicing in Honolulu, HI. Our medical registry currently tracks 10 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 459 documented patient claims. Among these therapy options, the most frequently utilized medication is Lumigan, which accounts for 128 claims alone.


Dorzolamide Hcl

Generic Formulation: Dorzolamide HclSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 18
30-Day Fills 33.4
Days Supply 1,000
HI State Average Benchmarks
Peer Average Claims44.0
Peer Average 30-Day Fills89.7
Peer Average Days Supply2,669
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 59.1% less volume than the regional standard for practitioners inside HI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $762.70 across this reporting matrix range.

Provider Avg Cost Per Claim

$42.37

State Avg Cost Per Claim

$29.42

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Dorzolamide is used to treat high pressure inside the eye due to glaucoma (open angle-type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. This medication works by decreasing the amount of fluid within the eye. It belongs to a class of drugs known as carbonic anhydrase inhibitors.

Latanoprost

Generic Formulation: LatanoprostSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 102
30-Day Fills 189.6
Days Supply 5,362
HI State Average Benchmarks
Peer Average Claims157.0
Peer Average 30-Day Fills331.6
Peer Average Days Supply9,608
Conservative Utilization

This provider writes prescriptions for this formulation 35.0% less frequently than the standard regional baseline metric for practitioners inside HI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $3,449.03 across this reporting matrix range.

Provider Avg Cost Per Claim

$33.81

State Avg Cost Per Claim

$27.88

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A prostaglandin F analog used to treat OCULAR HYPERTENSION in patients with GLAUCOMA.

Therapeutic Applications

Latanoprost is used to treat high pressure inside the eye due to glaucoma (open angle type) or other eye diseases (such as ocular hypertension). It is similar to a natural chemical in the body (prostaglandin) and works by regulating the flow of fluid within the eye which results in lower pressure. Lowering high pressure inside the eye helps to prevent blindness.

Levobunolol Hcl

Generic Formulation: Levobunolol HclSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 31
30-Day Fills 67.1
Days Supply 2,014
HI State Average Benchmarks
Peer Average Claims63.0
Peer Average 30-Day Fills137.6
Peer Average Days Supply4,123
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 50.8% less volume than the regional standard for practitioners inside HI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $809.60 across this reporting matrix range.

Provider Avg Cost Per Claim

$26.12

State Avg Cost Per Claim

$26.16

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used alone or with other medications to treat high pressure inside the eye due to glaucoma (open-angle type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. Levobunolol belongs to a class of drugs known as beta blockers and works by decreasing the amount of fluid production within the eye.

Lumigan

Generic Formulation: BimatoprostSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 128
30-Day Fills 248.3
Days Supply 7,321
HI State Average Benchmarks
Peer Average Claims42.0
Peer Average 30-Day Fills84.2
Peer Average Days Supply2,458
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 204.8% higher than the standard regional baseline profile for HI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $76,106.91 across this reporting matrix range.

Provider Avg Cost Per Claim

$594.59

State Avg Cost Per Claim

$612.64

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A cloprostenol-derived amide that is used as an ANTIHYPERTENSIVE AGENT in the treatment of OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.

Therapeutic Applications

Bimatoprost is used to treat high pressure inside the eye due to glaucoma (open-angle type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye can help prevent blindness. This medication works by regulating the flow of fluid within the eye to maintain a normal pressure.

Prolensa

Generic Formulation: Bromfenac SodiumSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 14
30-Day Fills 21.0
Days Supply 630
HI State Average Benchmarks
Peer Average Claims79.0
Peer Average 30-Day Fills120.9
Peer Average Days Supply3,522
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 82.3% less volume than the regional standard for practitioners inside HI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $4,520.88 across this reporting matrix range.

Provider Avg Cost Per Claim

$322.92

State Avg Cost Per Claim

$336.20

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat swelling (inflammation) and pain in the eye after a certain type of eye surgery (cataract surgery). Bromfenac belongs to a class of drugs known as nonsteroidal anti-inflammatory drugs (NSAIDs). It works by blocking the effects of certain natural substances (prostaglandins) that cause pain and inflammation.

Restasis

Generic Formulation: CyclosporineSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 29
30-Day Fills 65.0
Days Supply 1,950
HI State Average Benchmarks
Peer Average Claims66.0
Peer Average 30-Day Fills119.5
Peer Average Days Supply3,582
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 56.1% less volume than the regional standard for practitioners inside HI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $39,048.12 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,346.49

State Avg Cost Per Claim

$1,172.65

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A group of closely related cyclic undecapeptides from the fungi Trichoderma polysporum and Cylindocarpon lucidum. They have some antineoplastic and antifungal action and significant immunosuppressive effects. Cyclosporins have been proposed as adjuvants in tissue and organ transplantation to suppress graft rejection.

Therapeutic Applications

Cyclosporine eye drops are used to treat a certain type of dry eyes. They work by increasing the amount of tears you make.

Rhopressa

Generic Formulation: Netarsudil MesylateSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 75
30-Day Fills 120.1
Days Supply 3,259
HI State Average Benchmarks
Peer Average Claims43.0
Peer Average 30-Day Fills74.7
Peer Average Days Supply2,102
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 74.4% higher than the standard regional baseline profile for HI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $36,100.70 across this reporting matrix range.

Provider Avg Cost Per Claim

$481.34

State Avg Cost Per Claim

$608.51

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Netarsudil is used to treat high pressure inside the eye due to certain eye conditions (such as open-angle glaucoma, ocular hypertension). This medication is thought to work by increasing the flow of fluid out of the eye. This helps lower pressure inside the eye. Lowering high pressure inside the eye can help prevent loss of vision or blindness.

Rocklatan

Generic Formulation: Netarsudil Mesylat/LatanoprostSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 27
30-Day Fills 30.9
Days Supply 786
HI State Average Benchmarks
Peer Average Claims43.0
Peer Average 30-Day Fills72.7
Peer Average Days Supply2,018
Conservative Utilization

This provider writes prescriptions for this formulation 37.2% less frequently than the standard regional baseline metric for practitioners inside HI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $8,976.89 across this reporting matrix range.

Provider Avg Cost Per Claim

$332.48

State Avg Cost Per Claim

$654.17

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Netarsudil/latanoprost is used to treat high pressure inside the eye due to certain eye conditions (such as open-angle glaucoma, ocular hypertension). Lowering high pressure inside the eye can help prevent vision loss or blindness.

Timolol Maleate

Generic Formulation: Timolol MaleateSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 13
30-Day Fills 25.5
Days Supply 764
HI State Average Benchmarks
Peer Average Claims77.0
Peer Average 30-Day Fills166.2
Peer Average Days Supply4,920
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 83.1% less volume than the regional standard for practitioners inside HI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $727.29 across this reporting matrix range.

Provider Avg Cost Per Claim

$55.95

State Avg Cost Per Claim

$48.77

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A beta-adrenergic antagonist that is similar in action to PROPRANOLOL; the levo-isomer is more active. Timolol has been proposed as an anti-hypertensive, anti-arrhythmic, anti-angina, and anti-glaucoma agent. It is also used in the treatment of MIGRAINE DISORDERS and tremor.

Therapeutic Applications

This medication is used to treat high pressure inside the eye due to glaucoma (open angle-type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. This medication works by decreasing the amount of fluid within the eye. Timolol belongs to a class of drugs known as beta-blockers.

Vyzulta

Generic Formulation: Latanoprostene BunodSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 22
30-Day Fills 39.8
Days Supply 1,168
HI State Average Benchmarks
Peer Average Claims38.0
Peer Average 30-Day Fills65.2
Peer Average Days Supply1,872
Conservative Utilization

This provider writes prescriptions for this formulation 42.1% less frequently than the standard regional baseline metric for practitioners inside HI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $9,840.91 across this reporting matrix range.

Provider Avg Cost Per Claim

$447.31

State Avg Cost Per Claim

$515.72

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Latanoprostene bunod is used to treat high pressure inside the eye due to glaucoma (open-angle type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye can help prevent blindness. This medication works by controlling the flow of fluid within the eye to maintain a normal pressure.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. CARL T MINATOYA MD provides transparency into local medical care patterns within Honolulu, HI.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Ophthalmology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.